文献速递血栓与止血

静脉血栓栓塞症的核分子影像:靶向血栓特异性分子成分以改进诊疗

Nuclear molecular imaging of venous thromboembolism: targeting clot-specific molecular components for improved diagnosis and management.
PubMed 文献 · J Thromb Haemost · 2026-06-05

本文综述静脉血栓栓塞症(VTE)核分子影像的进展。现有结构或灌注影像只能定位血栓并评估血流动力学影响,难以反映血栓的生物学活性与新旧程度,导致抗凝疗程决策缺乏血栓特异性分子信息。靶向纤维蛋白或活化血小板的放射性探针结合SPECT与PET,有望直接显示血栓并提示其结构、新旧与活性,推动VTE管理从结构/灌注范式转向分子信息驱动范式。

要点

  • 现有VTE影像仅靠结构或灌注间接推断血栓,不反映血栓活性与新旧。
  • 靶向纤维蛋白或活化血小板的放射性探针可实现血栓直接分子显像。
  • 分子影像有望辅助抗凝疗程决策,但尚处研究阶段未进入常规临床。

核心结论

  • 核分子影像靶向血栓特异性成分,可望弥补现有影像缺乏血栓生物学信息的不足,推动VTE管理向分子信息驱动转变。

研究设计与样本

  • 综述类文章,围绕VTE核分子影像的现状与前景展开论述,未报告系统检索范围与样本量。

主要发现

  • 现有VTE诊断影像依赖结构或灌注技术,从血管结构异常或充盈缺损推断血栓。
  • 现有影像在定位血栓和评估血流动力学影响方面高效,但对血栓生物学活性或新旧程度提供的信息很少。
  • 抗凝策略的疗程与管理常在缺乏直接血栓特异性分子信息的情况下制定,可能导致结局欠佳及致命出血风险增加。
  • SPECT与PET靶向显像除提高诊断准确性外,预期可提供血栓结构、新旧与活性的信息。
  • 与高通量技术所得分子发现整合,可能进一步阐明血栓形成与溶解的细胞和分子机制。

临床怎么用

  • 目前核分子影像尚未提供可照搬的剂量、阈值或疗程推荐,临床决策仍以抗凝为基础。

局限性

  • 摘要为叙述性综述,未报告检索策略、纳入研究数量及定量汇总数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Venous thromboembolism (VTE), manifesting as deep vein thrombosis and pulmonary embolism, is a common, recurrent and potentially fatal condition. Anticoagulation remains the cornerstone of therapy, yet determining optimal treatment duration (eg, decision to shorten or extend anticoagulant treatment) is difficult due to the uncertain balance between long-term bleeding risk and recurrence. Future advances in vascular nuclear molecular imaging could critically help support this decision-making process. Current VTE diagnostic imaging relies on structural or perfusion-based techniques to infer thrombosis from abnormal vasculature structure or filling defects. While highly effective in localizing thrombi and assessing hemodynamic impact, they provide little insight into the biological activity or age of the clot. Consequently, anticoagulation strategies (duration and management) often proceed without direct clot-specific molecular information, potentially leading to suboptimal outcomes and increased risk of fatal bleeding. By contrast, nuclear VTE molecular imaging-using radiolabeled probes that selectively target key thrombus components such as fibrin or activated platelets-enables direct visualization of the clot. Single-photon emission computed tomography and positron emission tomography targeted imaging of VTE, beyond enhancing diagnostic accuracy, are expected to provide valuable insights into the structure, age, and activity of the clot. In particular, integration of these modalities with molecular findings from high throughput technologies could further elucidate the cellular and molecular mechanisms driving thrombus formation and resolution. When coupled with positron emission tomography's ability to assess molecular processes in vivo, such approaches may establish precision imaging biomarkers, bridging the gap between clot biology and clinical imaging, and ultimately transform VTE management from a structural or perfusion based to molecularly informed paradigm.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Elhasnaoui J, Robin P, Lemarie CA, et al. Nuclear molecular imaging of venous thromboembolism: targeting clot-specific molecular components for improved diagnosis and management. J Thromb Haemost. 2026. PMID: 42250882. doi:10.1016/j.jtha.2026.05.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。